Naphthyridine Compounds for Selective Akt Isoform Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods to inhibit Akt activity, such as PI3K inhibition, are non-specific and affect multiple kinases, while specific inhibitors for upstream kinases like PDK1 are lacking, leading to challenges in effectively targeting Akt isoforms in cancer treatment.
Innovation Solution
Development of substituted naphthyridine compounds that selectively inhibit one or two Akt isoforms, providing a targeted approach to modulate Akt activity for cancer treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PI3K inhibition is used to inhibit Akt activity, then Akt activation is blocked, but multiple PH domain-containing signaling molecules are indiscriminately affected
Solution Approach 1:
The patent uses ATP-competitive binding to the Akt kinase active site as an intermediary mechanism to achieve selective inhibition. Instead of blocking upstream PI3K signaling (which affects multiple downstream targets), the compounds directly target Akt's catalytic domain with high selectivity, preventing ATP binding and subsequent phosphorylation of substrates like BAD and GSK-3β without affecting other PH domain-containing proteins
Solution Approach 2:
The invention applies local quality by designing compounds that specifically interact with unique structural features of the Akt kinase domain. The substituted naphthyridine structure (Formula I) with specific substituents R1-R6 creates localized molecular interactions with Akt's ATP binding site that distinguish it from other kinases, enabling selective inhibition of Akt1, Akt2, and/or Akt3 isoforms while sparing other signaling molecules
2Reliability
If upstream kinase PDK1 is inhibited to block Akt activation, then Akt activity is reduced, but multiple PDK1-dependent protein kinases are affected
Solution Approach 1:
The patent employs direct binding to the Akt kinase active site as an intermediary approach, bypassing upstream PDK1 inhibition. The compounds in Formula I act as direct Akt inhibitors that compete with ATP for binding to the catalytic domain, providing selective suppression of Akt activity without affecting other PDK1 substrates such as SGK, S6 kinases, or atypical PKC isoforms
Solution Approach 2:
The invention achieves local quality through molecular design of the naphthyridine core structure with specific substituent patterns (R1-R6 groups) that create unique steric and electronic interactions with Akt's ATP binding pocket. This localized molecular recognition ensures high selectivity for Akt isoforms while avoiding off-target effects on other kinases
3Adaptability or versatility
If non-specific kinase inhibitors are used, then broad kinase activity is suppressed, but selectivity for Akt isoforms is lost
Solution Approach 1:
The patent implements local quality by designing the substituted naphthyridine compounds (Formula I) with specific molecular features that create localized interactions with Akt's unique structural elements. The core naphthyridine ring system with strategically positioned substituents (R1-R6) forms specific hydrogen bonds, hydrophobic interactions, and steric contacts with residues in the Akt ATP binding site that are not conserved in other kinases, achieving high selectivity for Akt1, Akt2, and/or Akt3 isoforms
Solution Approach 2:
The invention applies parameter changes by systematically varying the substituent parameters (R1-R6 groups) on the naphthyridine core to optimize binding affinity and selectivity for different Akt isoforms. By adjusting parameters such as substituent size, charge, and hydrophobicity at specific positions, the compounds can be fine-tuned to preferentially inhibit Akt1, Akt2, or Akt3 while maintaining selectivity against other kinases
Data Source
AI summary
The instant invention provides for substituted naphthyridine compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity by administering the compound to a patient in need of treatment of cancer.